Experimental Merck Pill Raises Hope of Preventing Coronavirus Deaths

An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS

An experimental antiviral pill developed by Merck & Co (MRK.N) could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, according to data that experts hailed as a potential breakthrough in how the virus is treated.

Click here to read more.

SOURCE: Reuters – Reporting by Deena Beasley and Carl O’Donnell; Additional reporting by Josephine Mason, and Ahmed Aboulenein; Editing by Lincoln Feast, Kirsten Donovan, Alexander Smith, Bill Berkrot and Sonya Hepinstall